# US 2021/0061909 A1 · Treatment of head and neck cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0061909 A1
- Document ID: US20210061909A1
- Status: Published application
- Kind: A1
- Application number: 16/979,323
- Filed: 2019-03-12
- Published: 2021-03-04
- Earliest claimed: 2018-03-13
- Assignees: Innate Pharma
- Applicants: Innate Pharma
- Inventors: Agnes BOYER-CHAMMARD; Pierre DODION; Roger COHEN
- Web page: https://patentgrep.com/patent/US20210061909A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61P 35/00: Antineoplastic agents
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/30: from tumour cells
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This invention relates to the use of NKG2A-targeting agents for the treatment of cancers, notably head and neck cancers, in a patient having received prior treatment with cetuximab. This invention also provides advantageous combination regimens for use with NKG2A-targeting agents for the treatment of cancers.

## Claims

### Claim 1

An agent that neutralizes the inhibitory activity of human NKG2A, for use in the treatment of a HNSCC in an individual having received prior treatment with cetuximab.

### Claim 2 (depends on 1)

The agent for use of claim 1, wherein the individual has a HNSCC cancer that has progressed despite prior treatment with cetuximab.

### Claim 3

The agent for use of any one of the above claims, wherein the individual has a HNSCC cancer that has progressed despite prior treatment with cetuximab combined with radiotherapy or chemotherapy.

### Claim 4

The agent for use of any one of the above claims, wherein the individual has a HNSCC cancer that has progressed despite prior treatment with cetuximab as single agent.

### Claim 5

The agent for use of any one of the above claims, wherein the individual has unresectable HNSCC.

### Claim 6

The agent for use of any one of the above claims, wherein the agent that neutralizes the inhibitory activity of human NKG2A is administered in combination with cetuximab.

### Claim 7

Cetuximab, for use in the treatment of a HNSCC in an individual having received prior treatment with cetuximab, wherein said treatment comprises administering to the individual an effective amount of each of: (a) an agent, optionally an antibody, that neutralizes the inhibitory activity of human NKG2A, and (b) cetuximab.

### Claim 8 (depends on 7)

The agent for use of claim 7, wherein the individual has unresectable HNSCC.

### Claim 9

An agent that neutralizes the inhibitory activity of human NKG2A for use in treating a cancer in a human individual having an unresectable, optionally non-metastatic, HNSCC, optionally wherein the HNSCC is cetuximab-resistant, the treatment comprising administering to the individual an effective amount of each of: (a) an agent, optionally an antibody, that neutralizes the inhibitory activity of human NKG2A, and (b) cetuximab.

### Claim 10

The agent for use of any one of the above claims, wherein the individual has HNSCC cancer that has progressed despite prior treatment with cetuximab.

### Claim 11

The agent for use of any one of the above claims, wherein the individual has HNSCC cancer that has progressed despite prior treatment with cetuximab combined with radiotherapy.

### Claim 12

The agent for use of any one of the above claims, wherein the treatment of a HNSCC in an individual comprises:
a) determining whether an individual has a HNSCC that is resistant to cetuximab (e.g. as single agent or in combination with radiotherapy and/or a chemotherapeutic agent), and
b) upon the determination that the individual has HNSCC that is resistant to cetuximab, administering to the individual: (i) an agent, optionally an antibody, that neutralizes the inhibitory activity of human NKG2A, and (ii) cetuximab.

### Claim 13

The agent for use of any of the above claims, wherein the treatment of a HNSCC in an individual comprises:
a) determining whether HLA-E polypeptide is expressed by malignant cells from the individual having a HNSCC, and
b) upon the determination that malignant cells express HLA-E polypeptide, administering to the individual (i) an agent, optionally an antibody, that neutralizes the inhibitory activity of human NKG2A, and ii) cetuximab.

### Claim 14 (depends on 13)

The agent for use of claim 13, wherein determining whether HLA-E polypeptide is expressed by malignant cells comprises obtaining from the individual a biological sample that comprises HNSCC cells, bringing said cells into contact with an antibody that binds a HLA-E polypeptide, and detecting cells that express HLA-E.

### Claim 15

The agent for use of any one of the above claims, wherein the agent that neutralizes the inhibitory activity of human NKG2A is an anti-NKG2A antibody.

### Claim 16 (depends on 15)

The agent for use of claim 15, wherein the anti-NKG2A antibody is characterized by a reduction in binding to a mutant NKG2A polypeptide having the substitutions K199A/D202A/V213S/R215A/K217A (reference to SEQ ID NO: 1), compared to a wild-type NKG2A polypeptide (SEQ ID NO: 1).

### Claim 17 (depends on 15, 16)

The agent for use of claim 15 or 16, wherein the anti-NKG2A antibody comprises a human IgG4 constant region.

### Claim 18 (depends on 15, 16, 17)

The agent for use of any one of claims 15-17, wherein the anti-NKG2A antibody comprises an Fc-engineered constant region comprising an amino acid modification that reduces binding to a human Fcγ receptor.

### Claim 19 (depends on 15, 16, 17, 18)

The agent for use of any one of claims 15-18, wherein the anti-NKG2A antibody competes with the antibodies having the heavy and light chains comprising SEQ ID NOS: 2 and 7, respectively, for binding to human NKG2A.

### Claim 20 (depends on 15, 16, 17, 18, 19)

The agent for use of any one of claims 15-19, wherein the anti-NKG2A antibody comprises the CDR1, CDR2 and CDR3 domains of a heavy chain having the sequence set forth in SEQ ID NO: 2, and the CDR1, CDR2 and CDR3 domains of a light chain having the sequence set forth in SEQ ID NO: 7.

### Claim 21 (depends on 15, 16, 17, 18, 19, 20)

The agent for use of any one of claims 15-20, wherein the anti-NKG2A antibody is administered as a pharmaceutically acceptable composition comprising a therapeutically effective amount of the anti-NKG2A antibody.

### Claim 22 (depends on 21)

The agent for use of claim 21, wherein the composition is free of any other pharmaceutically active agents.

### Claim 23

The agent for use of any one of the above claims, wherein the anti-NKG2A antibody is administered several times at a dosing frequency from once about every week to once about every month.

### Claim 24

The agent for use of any one of the above claims, wherein cetuximab is administered weekly.

### Claim 25

The agent for use of any one of the above claims, wherein the treatment comprises at least one administration cycle, wherein the agent that neutralizes the inhibitory activity of human NKG2A is administered every two weeks and cetuximab is administered weekly.

### Claim 26

The agent for use of any one of the above claims, wherein the treatment comprises at least one period of two weeks, wherein for each of the at least one period, the antibody that neutralizes the inhibitory activity of human NKG2A is administered at a dose of 1-10 mg/kg body weight, and cetuximab is administered in an initial dose of 400 mg/m2, and subsequently weekly at 250 mg/m2.

### Claim 27

The agent for use of any one of the above claims, wherein the treatment comprises at least one period of two weeks, wherein for each of the at least one period, the antibody that neutralizes the inhibitory activity of human NKG2A is administered at a fixed dose between 100-1000 mg, optionally 750 mg, and cetuximab is administered in an initial dose of 400 mg/m2, and subsequently weekly at 250 mg/m2.
